Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. sean.o'
Vaccine. 2012 Nov 6;30(48):6731-3. doi: 10.1016/j.vaccine.2012.08.075. Epub 2012 Sep 10.
Measles-mumps-rubella-varicella (MMRV) vaccine is associated with increased febrile seizure risk compared with measles-mumps-rubella and varicella vaccine given separately (MMR+V) in children 12-15-month old. We assessed knowledge regarding MMRV and febrile seizures, intended practices, and factors influencing the decision to recommend MMRV.
National survey administered 10/2008-1/2009 of US pediatricians (Peds) and family physicians (FP).
Response rate was 73% (620/849). Twenty-nine percent of Peds and 74% of FP (p<0.001) were unaware of increased febrile seizure risk after MMRV. After reading an informational statement, 20% of Peds and 7% of FP (p<0.001) would recommend MMRV to a healthy 12-15-month-old child. The factor most frequently reported as "very important" in the decision to recommend MMRV or MMR+V was ACIP/AAFP/AAP recommendations (pediatricians, 77%, family physicians, 73%, p=0.08).
After receiving data regarding febrile seizure risk after MMRV, few physicians report they would recommend MMRV to a healthy 12-15-month-old child.
与分别接种麻疹-腮腺炎-风疹-水痘（MMRV）疫苗和麻疹-腮腺炎-风疹（MMR）疫苗相比，12-15 月龄儿童接种 MMRV 疫苗与发热性惊厥风险增加相关。我们评估了与 MMRV 和发热性惊厥相关的知识、预期做法以及影响推荐 MMRV 疫苗决策的因素。
2008 年 10 月至 2009 年 1 月，对美国儿科医生（Peds）和家庭医生（FP）进行了全国性调查。
应答率为 73%（620/849）。29%的儿科医生和 74%的家庭医生（p<0.001）不知道 MMRV 后发热性惊厥风险增加。阅读信息声明后，20%的儿科医生和 7%的家庭医生（p<0.001）会向健康的 12-15 月龄儿童推荐 MMRV。在决定推荐 MMRV 或 MMR+V 时，最常被报告为“非常重要”的因素是 ACIP/AAFP/AAP 建议（儿科医生为 77%，家庭医生为 73%，p=0.08）。
在获得 MMRV 后发热性惊厥风险的数据后，很少有医生报告他们会向健康的 12-15 月龄儿童推荐 MMRV。
